ArticleBone marrow transplantation2020

Pre-emptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes.

Nicolas Stocker et al.PubMed ↗Publisher ↗

No numbers read from the abstract.